Our Market |

“Millions of people in the U.S. and around the world are currently experiencing stress-related disorders, anxiety, depression, debilitating pain, or some form of cardiovascular disease.  This is the market we aim to impact with our discovery.”

Global Market Impact

Stress, anxiety, depression, bipolar disorder, post-traumatic stress disorder (PTSD), pain, other CNS disorders, and related comorbid conditions represent some of the most significant health problems of the 21st century. As much as 75-90% of these disorders are stress-related, with predisposition and vulnerability having both genetic and epigenetic origins. Nearly 40 million people in the U.S. alone experience an anxiety disorder, with over half experiencing medium to severe anxiety.

Depression, whether a primary or comorbid condition, is a highly prevalent disorder affecting more than 350 million people globally, with as many as 40 million people in the United States. Depression affects approximately 50% of patients with anxiety, bipolar disorder, and schizophrenia; 35-50% of chronic pain patients; >40% of PTSD patients, 25% of cancer patients, 50% of Parkinson's disease patients, and 33% of patients who have experienced a heart attack.

Pain affects approximately 100 million U.S. patients with approximately 30-40 million patients experiencing severe to debilitating pain, creating an economic burden exceeding $600 billion per year. Patients with chronic pain disorders are 3-4 times more likely to experience depression than the general population.

More than 80 million people in the United States have some form of cardiovascular disease (CVD), such as coronary heart disease, stroke, high blood pressure, or heart failure. CVDs requiring anticoagulant therapy include atrial fibrillation (AFib), the most common heart arrhythmia affecting an estimated 3-6 million people, and venous thromboembolism affecting nearly 1 million people annually.